---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-290445"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2022-11-22T23:59:59+00:00"
generated_at: "2026-06-21T14:30:47.122417+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# XOMA acquires ebopiprant from ObsEva for $15M cash plus milestone earn-outs

## Summary
- XOMA pays $15M cash at closing to ObsEva for ebopiprant; assumes IP estate and all license agreements including Organon sublicense.
- XOMA eligible for up to $475M in development, regulatory, and sales milestones from Organon; will pay ObsEva up to $98M of those.
- Upon commercialization, XOMA receives low- to mid-teen royalties from Organon and pays mid-single-digit royalty to Merck KGaA.

## SEC filing metadata
- accession: 0001193125-22-290445
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2022-11-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312522290445/0001193125-22-290445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312522290445/d396302d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-290445
- JSON: https://secwatch.observer/filing/0001193125-22-290445.json
- Plain text: https://secwatch.observer/filing/0001193125-22-290445.txt

## Key facts
- Material Agreements
  XOMA Royalty Corp entered into Intellectual Property Acquisition Agreement with ObsEva SA valued at $15 million upfront plus up to $98 million in milestone payments (effective 2022-11-21).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: ObsEva SA
  - Value: $15 million upfront plus up to $98 million in milestone payments
  - Effective: 2022-11-21
  source text: On November 21, 2022, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into an intellectual property acquisition agreement (the “Agreement”) with ObsEva, SA, a Swiss biotech company (“ObsEva”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/791908/000119312522290445/0001193125-22-290445-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.